Stockscreener 앱 받기
0.5183
13.31%
-0.0796
시간 외 거래:
.52
0.0017
+0.33%
전일 마감가:
$0.5979
열려 있는:
$0.5871
하루 거래량:
489.91K
Relative Volume:
0.54
시가총액:
$10.08M
수익:
$4.71M
순이익/손실:
$-11.79M
주가수익비율:
-0.1548
EPS:
-3.3492
순현금흐름:
$-9.72M
1주 성능:
-1.65%
1개월 성능:
+15.74%
6개월 성능:
+1.63%
1년 성능:
-79.83%
1일 변동 폭
$0.503
$0.5871
1주일 범위
$0.4854
$0.62
52주 변동 폭
$0.23
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
명칭
Ensysce Biosciences Inc
전화
(858) 263-4196
주소
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.5183 | 10.08M | 4.71M | -11.79M | -9.72M | -3.3492 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
A study plan for a pain condition with no treatment that cures it reaches UK regulators. - stocktitan.net
More than 320 pain professionals attended Ensysce’s symposium on complex pain. - Stock Titan
Ensysce Biosciences Inc (NASDAQ: ENSC) Share Price, ENSC Stock News, ENSC Share Price & Updates - kalkine.com.au
A doctor from Ensysce is among a limited group chosen to speak at an FDA psychedelic hearing - Stock Titan
ORCL: Oracle Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
An FDA hearing on psychedelic drugs is set for Sept. 14. Ensysce will take part. - Stock Titan
Ensysce completes PF614-MPAR-102 clinical enrollment - grafa.com
Ensysce completes enrollment in opioid overdose study By Investing.com - Investing.com Australia
Ensysce completes enrollment in opioid overdose study - Investing.com India
Ensysce completes enrollment in opioid overdose study By Investing.com - Investing.com Canada
Ensysce completes enrollment in opioid overdose study - Investing.com
An opioid study from Ensysce is fully enrolled to test overdose protection - stocktitan.net
Ensysce Biosciences, Inc. (ENSC) Stock Price & News - Syfe
Ensysce Faces Nasdaq Delisting Risk After Cy Biopharma Deal Triggers Change of Control - minichart.com.sg
Ensys receives Nasdaq compliance notices but cleared equity rule; granted bid-price extension - TradingView
Ensysce Biosciences raises $21M in initial tranche, meets Nasdaq equity rules, seeks second bid-price grace period - TradingView
Ensysce (ENSC) completes private raise with contingent proceeds - Stock Titan
Ensysce (ENSC) Results Versus Estimates: The Bottom-Line Figure Beats Its Comparison in the Latest Reading; After Earnings: The Stock Ends Down 3.87% for the Current SessionEarnings Yield Spread - vinanet.vn
Ensysce (ENSC) chair boosts stake, locks in votes on merger - Stock Titan
ENSC: Acquisition and financing position CY200 for CRPS advancement, extending cash runway to 2027 - TradingView
ENSC: Acquisition and financing position CY200 for Phase II CRPS trial and long-term pipeline growth - TradingView
Ensysce Biosciences director Gower buys $444,169 in company stock - Investing.com
Ensysce Biosciences director Gower buys $444,169 in company stock - Investing.com
Ensysce Biosciences Insider Bought Shares Worth $444,169, According to a Recent SEC Filing - marketscreener.com
Ensysce Biosciences (ENSC) director buys stock and converts debt - Stock Titan
Ensysce Biosciences director Bob G. Gower acquires common shares worth $443,025.17 - Bitget
Ensysce Biosciences earnings beat by $0.51, revenue fell short of estimates - Investing.com Canada
Ensysce Biosciences earnings beat by $0.51, revenue fell short of estimates - Investing.com
MSN Money - MSN
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
Ensysce Completes Cy Biopharma Acquisition Adding Lead CRPS Candidate - Minichart
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Ensysce Q2 EPS beats; completes Cy Biopharma acquisition for $38.6m - scanx.trade
Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal - Stock Titan
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com Canada
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com India
Ensysce Biosciences Q2 net loss widens on higher R&D costs - TradingView
ENSC: Acquisition and new funding extend cash runway, with clinical pipeline and losses both increasing - TradingView
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com UK
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - FinancialContent
ENSC Q1 2026 Earnings: Narrower-than-Expected Loss Marks 30% Beat Amid Persistent Share Weakness - vinanet.vn
Cy Biopharma merges with Ensysce Biosciences - Startupticker.ch
Ensysce Biosciences (ENSC) officer reports 154.8M underlying common via preferred - Stock Titan
Ensysce Biosciences Acquires Cy Biopharma to Expand Pain Pipeline - sekbernews.id
Orrick Advises Cy Biopharma on Acquisition by Ensysce Biosciences and up to $77 Million Private Financing - orrick.com
Ensysce Biosciences Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Form 8K Ensysce Biosciences Inc For: 6 August By Investing.com - Investing.com South Africa
Ensysce Biosciences (ENSC) Drifts Lower as Shares Test Support Near $0.49Factor Rotation - careplusvn.com
Ensysce Biosciences (ENSC) Drifts Lower as Shares Test Support Near $0.49Last Point Resistance - vinanet.vn
Form 8K Ensysce Biosciences Inc For: 6 August By Investing.com - Investing.com Nigeria
Ensysce Biosciences Inc (ENSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ensysce Biosciences Inc 주식 (ENSC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GOWER BOB G | Director |
Aug 07 '26 |
Buy |
0.49 |
400,000 |
198,000 |
916,740 |
4.22%
자본화:
|
볼륨(24시간):